Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Anusuya Lahiri

Analysts Remain Bullish On Cardlytics Post Q4 Results

  • Analysts reiterated a Buy on Cardlytics Inc (NASDAQ:CDLXpost Q4 results.
  • Craig-Hallum analyst Jason Kreyer lowered the firm's price target on Cardlytics from $100 to $70 (15% upside) and kept a Buy.
  • The analyst notes quarterly results were strong despite lingering concerns over the supply chain, labor shortages, and omicron issues faced in the quarter. 
  • That said, management is leaning into the opportunity with direct investments into sales talent, engineering, and retention. The result is further delays in profitability, Kreyer notes.
  • Despite an outlook for substantially higher revenue this year, he adds that EBITDA losses will exceed last year to afford these investments.
  • Needham analyst Kyle Peterson maintained Cardlytics with a Buy and lowered the price target from $120 to $85 (39% upside).
  • Price Action: CDLX shares traded higher by 13.75% at $61.14 on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.